Roche: The clinical study of liver cancer stage III TALENTACE has achieved the main research endpoint.

Roche announced that the phase III TALENTACE study has reached its primary endpoint, which evaluated the efficacy and safety of atezolizumab, bevacizumab, and on-demand transarterial chemoembolization in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. The study showed statistically and clinically significant improvements in the primary endpoint of TACE progression-free survival, with overall survival not yet mature at the time of mid-term analysis. Additionally, a clinically meaningful improvement in progression-free survival evaluated by RECIST v1.1 was also observed.